Two glycoengineered variants of the L1CAM‐targeting radioimmunoconjugate [89Zr]Zr‐DFO‐HuE71 were used more recently by Sharma et al. (Figure5) to demonstrate the effectiveness of this strategy.[56] The afucosylated version with greater FcγRIIIA binding displayed higher accumulation in the liver and lymphoid organs and decreased tumor uptake compared to the parent radioimmunoconjugate. The gene discussed is FCGR3A; the disease is neoplasm.